Celltrion's COVID-19 treatment substance shows efficacy
SEOUL, Oct. 12 (Yonhap) -- Celltrion Inc., a leading South Korean pharmaceutical company, said Monday it will conduct additional clinical trials for its coronavirus antibody treatment substance.
The substance, called CT-P59, will be administered to some 1,000 people, including asymptomatic COVID-19 patients and those who had close contacts with COVID-19 patients.
The clinical trials come after the company successfully completed a phase one clinical trial on 32 healthy volunteers who have not contracted the COVID-19 virus.
Separately, CT-P59 is currently undergoing phase two and three trials both at home and abroad.
The company is currently conducting phase two trials on around 300 people with mild and severe symptoms of the virus, which will allow researchers to better check CT-P59's efficacy against COVID-19 and its overall safety.
The phase three trial will be carried out on around 720 people to see if the candidate material is actually effective against viral infections, according to the pharmaceutical giant.
Celltrion said that besides South Korea, it has requested clinical trials of CT-P59 in the United States, Romania and three other countries as part of its ongoing efforts to find viable treatment materials to fight the COVID-19 pandemic.
khj@yna.co.kr
(END)
-
New BTS song 'Film Out' tops Japan's Oricon weekly chart
-
'Dynamite' becomes 3rd BTS video to top 1 bln views
-
S. Korea, U.S. authorities assess N.K. has completed building new 3,000-ton submarine: sources
-
Mamamoo to hold online concert on British streaming platform next month
-
'Fake Love' becomes 4th BTS video to top 900 mln views
-
(Yonhap Feature) How young voters, once solid supporters of liberal causes, turned against Moon's party in by-elections
-
From Rose to Baekhyun, K-pop group idols also shine as solo acts
-
Moon takes election rout as 'reprimand' from the public, Cheong Wa Dae says
-
Boy band TXT to perform on Ellen DeGeneres show in latest global push
-
BTS to stream concerts in weekend Bang Bang Con event
-
S. Korea voices 'grave concerns' over Japan's expected decision to release Fukushima water into sea
-
S. Korea, U.S. closely watching N. Korean moves on SLBMs, new submarine: JCS
-
(LEAD) Seoul mayor pushes for introduction of self-testing kits, extending hours for small businesses
-
(LEAD) New virus cases under 600 for 2nd day; spring resurgence in store
-
S. Korea expresses 'strong regret' over Japan's decision to release water from Fukushima